BioLife Solutions Inc (BLFS) - Net Assets
Based on the latest financial reports, BioLife Solutions Inc (BLFS) has net assets worth $371.89 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($405.88 Million) and total liabilities ($34.00 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Explore cash flow conversion of BioLife Solutions Inc to assess how effectively this company generates cash.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $371.89 Million |
| % of Total Assets | 91.62% |
| Annual Growth Rate | 24.88% |
| 5-Year Change | -21.93% |
| 10-Year Change | 11646.3% |
| Growth Volatility | 662.82 |
BioLife Solutions Inc - Net Assets Trend (1988–2025)
This chart illustrates how BioLife Solutions Inc's net assets have evolved over time, based on quarterly financial data. Explore BLFS long-term investments to assets to see how much of total assets are deployed in long-term investments.
Annual Net Assets for BioLife Solutions Inc (1988–2025)
The table below shows the annual net assets of BioLife Solutions Inc from 1988 to 2025. For live valuation and market cap data, see BioLife Solutions Inc (BLFS) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $371.89 Million | +6.59% |
| 2024-12-31 | $348.91 Million | +3.33% |
| 2023-12-31 | $337.66 Million | -7.28% |
| 2022-12-31 | $364.19 Million | -23.55% |
| 2021-12-31 | $476.37 Million | +132.09% |
| 2020-12-31 | $205.25 Million | +147.21% |
| 2019-12-31 | $83.03 Million | +92.42% |
| 2018-12-31 | $43.15 Million | +327.55% |
| 2017-12-31 | $10.09 Million | +218.76% |
| 2016-12-31 | $3.17 Million | -67.89% |
| 2015-12-31 | $9.86 Million | -29.25% |
| 2014-12-31 | $13.94 Million | +205.01% |
| 2013-12-31 | $-13.27 Million | -6.29% |
| 2012-12-31 | $-12.49 Million | -11.68% |
| 2011-12-31 | $-11.18 Million | -17.09% |
| 2010-12-31 | $-9.55 Million | -22.00% |
| 2009-12-31 | $-7.83 Million | -51.36% |
| 2008-12-31 | $-5.17 Million | -109.37% |
| 2007-12-31 | $-2.47 Million | -1471.42% |
| 2006-12-31 | $180.09K | +368.00% |
| 2005-12-31 | $38.48K | -93.72% |
| 2004-12-31 | $612.96K | -54.80% |
| 2003-12-31 | $1.36 Million | +344.68% |
| 2002-12-31 | $-554.25K | -278.35% |
| 2001-12-31 | $310.77K | -91.44% |
| 2000-12-31 | $3.63 Million | +343.37% |
| 1999-12-31 | $818.40K | -42.83% |
| 1998-12-31 | $1.43 Million | -41.81% |
| 1997-12-31 | $2.46 Million | -38.40% |
| 1996-12-31 | $3.99 Million | +0.31% |
| 1995-12-31 | $3.98 Million | 0.00% |
| 1994-12-31 | $3.98 Million | -24.87% |
| 1993-12-31 | $5.30 Million | -5.36% |
| 1992-12-31 | $5.60 Million | -53.33% |
| 1991-12-31 | $12.00 Million | +118.18% |
| 1990-12-31 | $5.50 Million | +66.67% |
| 1989-12-31 | $3.30 Million | +3200.00% |
| 1988-12-31 | $100.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioLife Solutions Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33919600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00K | 0.01% |
| Other Comprehensive Income | $132.00K | 0.04% |
| Other Components | $711.40 Million | 191.30% |
| Total Equity | $371.89 Million | 100.00% |
BioLife Solutions Inc Competitors by Market Cap
The table below lists competitors of BioLife Solutions Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bangkok Life Assurance Public Company Limited
F:XBLA
|
$956.24 Million |
|
Xuchang Yuandong Drive Shaft Co Ltd
SHE:002406
|
$956.35 Million |
|
HangZhou Radical Energy Saving Technology Co Ltd
SHE:300652
|
$956.44 Million |
|
Elopak AS
OL:ELO
|
$956.62 Million |
|
Medartis Holding AG
SW:MED
|
$956.09 Million |
|
BURFORD CAPITAL LTD
F:9BFA
|
$954.83 Million |
|
YD More Investments Ltd
TA:MRIN
|
$954.78 Million |
|
Hangzhou Pinming Software Co. Ltd. A
SHG:688109
|
$954.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioLife Solutions Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 348,909,000 to 371,888,000, a change of 22,979,000 (6.6%).
- Net loss of 12,130,000 reduced equity.
- Other comprehensive income increased equity by 108,000.
- Other factors increased equity by 35,001,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.13 Million | -3.26% |
| Other Comprehensive Income | $108.00K | +0.03% |
| Other Changes | $35.00 Million | +9.41% |
| Total Change | $- | 6.59% |
Book Value vs Market Value Analysis
This analysis compares BioLife Solutions Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.20x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 434.95x to 3.20x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1988-12-31 | $0.06 | $24.50 | x |
| 1989-12-31 | $1.86 | $24.50 | x |
| 1990-12-31 | $3.10 | $24.50 | x |
| 1991-12-31 | $6.80 | $24.50 | x |
| 1992-12-31 | $3.17 | $24.50 | x |
| 1993-12-31 | $3.00 | $24.50 | x |
| 1994-12-31 | $2.26 | $24.50 | x |
| 1995-12-31 | $2.26 | $24.50 | x |
| 1996-12-31 | $2.26 | $24.50 | x |
| 1997-12-31 | $1.04 | $24.50 | x |
| 1998-12-31 | $0.60 | $24.50 | x |
| 1999-12-31 | $0.34 | $24.50 | x |
| 2000-12-31 | $5.12 | $24.50 | x |
| 2001-12-31 | $0.35 | $24.50 | x |
| 2002-12-31 | $-0.63 | $24.50 | x |
| 2003-12-31 | $1.53 | $24.50 | x |
| 2004-12-31 | $0.69 | $24.50 | x |
| 2005-12-31 | $0.04 | $24.50 | x |
| 2006-12-31 | $0.05 | $24.50 | x |
| 2007-12-31 | $-0.50 | $24.50 | x |
| 2008-12-31 | $-1.04 | $24.50 | x |
| 2009-12-31 | $-1.57 | $24.50 | x |
| 2010-12-31 | $-1.92 | $24.50 | x |
| 2011-12-31 | $-2.25 | $24.50 | x |
| 2012-12-31 | $-2.51 | $24.50 | x |
| 2013-12-31 | $-2.65 | $24.50 | x |
| 2014-12-31 | $1.33 | $24.50 | x |
| 2015-12-31 | $0.70 | $24.50 | x |
| 2016-12-31 | $0.25 | $24.50 | x |
| 2017-12-31 | $0.76 | $24.50 | x |
| 2018-12-31 | $2.65 | $24.50 | x |
| 2019-12-31 | $4.27 | $24.50 | x |
| 2020-12-31 | $7.52 | $24.50 | x |
| 2021-12-31 | $12.49 | $24.50 | x |
| 2022-12-31 | $8.57 | $24.50 | x |
| 2023-12-31 | $7.72 | $24.50 | x |
| 2024-12-31 | $7.57 | $24.50 | x |
| 2025-12-31 | $7.64 | $24.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioLife Solutions Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -3.26%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.61%
- • Asset Turnover: 0.24x
- • Equity Multiplier: 1.09x
- Recent ROE (-3.26%) is above the historical average (-147.33%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1988 | -500.00% | -500.00% | 0.20x | 5.00x | $-510.00K |
| 1989 | -51.52% | -1700.00% | 0.03x | 1.06x | $-2.03 Million |
| 1990 | -47.27% | -2600.00% | 0.02x | 1.02x | $-3.15 Million |
| 1991 | -39.17% | -4700.00% | 0.01x | 1.08x | $-5.90 Million |
| 1992 | -117.86% | -111.86% | 0.70x | 1.50x | $-7.16 Million |
| 1993 | -49.06% | -19.40% | 1.47x | 1.72x | $-3.13 Million |
| 1994 | -56.02% | -16.41% | 1.62x | 2.11x | $-2.63 Million |
| 1995 | -56.02% | -16.41% | 1.62x | 2.11x | $-2.63 Million |
| 1996 | -55.85% | -16.41% | 2.25x | 1.51x | $-2.63 Million |
| 1997 | -64.62% | -44.52% | 0.92x | 1.58x | $-1.84 Million |
| 1998 | -88.59% | -53.52% | 0.87x | 1.91x | $-1.41 Million |
| 1999 | -143.66% | -66.18% | 0.82x | 2.64x | $-1.26 Million |
| 2000 | -76.39% | -233.03% | 0.30x | 1.10x | $-3.13 Million |
| 2001 | -1419.16% | -328.14% | 0.76x | 5.72x | $-4.44 Million |
| 2002 | 0.00% | 25.43% | 2.70x | 0.00x | $271.30K |
| 2003 | -96.11% | -215.25% | 0.20x | 2.19x | $-1.44 Million |
| 2004 | -121.24% | -118.58% | 0.75x | 1.36x | $-804.46K |
| 2005 | -1609.43% | -100.75% | 1.37x | 11.62x | $-623.17K |
| 2006 | -629.70% | -187.99% | 1.08x | 3.11x | $-1.15 Million |
| 2007 | 0.00% | -293.31% | 1.34x | 0.00x | $-2.60 Million |
| 2008 | 0.00% | -209.84% | 1.13x | 0.00x | $-2.26 Million |
| 2009 | 0.00% | -175.03% | 1.19x | 0.00x | $-1.99 Million |
| 2010 | 0.00% | -95.30% | 1.59x | 0.00x | $-1.03 Million |
| 2011 | 0.00% | -70.93% | 1.66x | 0.00x | $-838.59K |
| 2012 | 0.00% | -29.31% | 1.79x | 0.00x | $-410.98K |
| 2013 | 0.00% | -12.11% | 2.67x | 0.00x | $242.99K |
| 2014 | -23.09% | -51.98% | 0.39x | 1.15x | $-4.61 Million |
| 2015 | -49.53% | -65.34% | 0.52x | 1.45x | $-5.06 Million |
| 2016 | -217.15% | -83.57% | 1.04x | 2.50x | $-7.19 Million |
| 2017 | -24.92% | -22.82% | 0.91x | 1.20x | $-3.52 Million |
| 2018 | 7.57% | 16.54% | 0.43x | 1.05x | $-1.05 Million |
| 2019 | -2.00% | -6.05% | 0.29x | 1.12x | $-9.96 Million |
| 2020 | 1.30% | 5.55% | 0.20x | 1.14x | $-17.86 Million |
| 2021 | -1.85% | -7.48% | 0.22x | 1.15x | $-56.98 Million |
| 2022 | -38.39% | -183.38% | 0.17x | 1.24x | $-176.22 Million |
| 2023 | -19.67% | -87.57% | 0.18x | 1.22x | $-100.19 Million |
| 2024 | -5.78% | -24.54% | 0.21x | 1.14x | $-55.07 Million |
| 2025 | -3.26% | -12.61% | 0.24x | 1.09x | $-49.32 Million |
Industry Comparison
This section compares BioLife Solutions Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $889,371,948
- Average return on equity (ROE) among peers: -44.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioLife Solutions Inc (BLFS) | $371.89 Million | -500.00% | 0.09x | $956.22 Million |
| Akoya Biosciences Inc (AKYA) | $53.77 Million | -117.77% | 2.35x | $64.44 Million |
| Align Technology Inc (ALGN) | $847.93 Million | 16.98% | 0.37x | $11.67 Billion |
| AngioDynamics Inc (ANGO) | $391.35 Million | 3.15% | 0.08x | $447.90 Million |
| AptarGroup Inc (ATR) | $1.42 Billion | 13.69% | 1.37x | $7.36 Billion |
| AtriCure Inc (ATRC) | $30.69 Million | -44.69% | 0.27x | $1.36 Billion |
| Avinger Inc (AVGR) | $-143.87 Million | 0.00% | 0.00x | $1.52 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |
| Avantor Inc (AVTR) | $-3.05 Billion | 0.00% | 0.00x | $5.44 Billion |
| Azenta Inc (AZTA) | $607.64 Million | 10.30% | 0.26x | $885.88 Million |
| Baxter International Inc (BAX) | $8.73 Billion | 12.63% | 1.29x | $9.95 Billion |
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, inc… Read more